Response to Comments: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

This document (A59144) is a response to public comments on the MolDX Local Coverage Determination (DL39007/L39007) concerning molecular biomarkers to risk-stratify patients at increased risk for prostate cancer. It records the comment period (05/20/2021–07/03/2021), notice period start (06/23/2022), and LCD effective date (08/08/2022), and notes a revision to the LCD title. No specific clinical coverage criteria, limitations, documentation requirements, or frequency limits are contained in this response.